Apixaban
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Venous Thromboembolism
Conditions
Venous Thromboembolism, Multiple Myeloma
Trial Timeline
Feb 28, 2018 → Nov 19, 2019
NCT ID
NCT02958969About Apixaban
Apixaban is a approved stage product being developed by Bristol Myers Squibb for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT02958969. Target conditions include Venous Thromboembolism, Multiple Myeloma.
What happened to similar drugs?
5 of 20 similar drugs in Venous Thromboembolism were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05187286 | Pre-clinical | Active |
| NCT03594045 | Phase 2 | Terminated |
| NCT02958969 | Approved | Completed |
| NCT03456648 | Phase 2 | Completed |
| NCT02714855 | Pre-clinical | Completed |
| NCT02345343 | Pre-clinical | Completed |
| NCT01885585 | Pre-clinical | Completed |
| NCT02153424 | Pre-clinical | Withdrawn |
| NCT02101112 | Phase 1 | Completed |
| NCT01884350 | Approved | Completed |
| NCT01885598 | Pre-clinical | Completed |
| NCT00252005 | Phase 2 | Completed |
Competing Products
20 competing products in Venous Thromboembolism